Scotia Vision LLC and i2eye Consulting LLC are merging in a move designed to strengthen the former company?s business model. The combined entity will be known as Scotia Vision.
Tampa, FL-Scotia Vision LLC and i2eye Consulting LLC are merging in a move designed to strengthen the former company’s business model. The combined entity will be known as Scotia Vision.
Michael O’Rourke and Susan Benton, founders and managing partners of Scotia Vision and i2eye, respectively, will be equal partners in the new entity. They have a combined experience of 30 years in the ophthalmic industry.
Before establishing Scotia Vision, a consultant to pharmaceutical, drug delivery, and device companies, O’Rourke was general manager of the Bausch + Lomb (B+L) U.S. pharmaceutical division. Before i2eye Consulting, which advises ophthalmic companies on commercialization matters, Benton was co-founder and senior vice president of commercial operations for Sirion Therapeutics. She also worked for B+L as the head of pharmaceutical sales and commercial operations, where she launched the company’s first branded pharmaceutical products.
“This transaction reinforces current strengths of Scotia Vision and the strategy to create a world-class ophthalmic practice,” said O’Rourke.
Benton added, “Merging makes a great deal of sense. Our combined consulting practice provides a scalable alternative to Tier 1 corporate service companies, which usually pursue larger multi-service opportunities.”
The company will be exhibiting (Booth 122) May 1 to 5 at the Association for Research in Vision and Ophthalmology annual meeting in Fort Lauderdale, FL.